- Conditions
- Vomiting, Nausea, Children, Only
- Interventions
- Inhaled Isopropyl Alcohol, Oral Ondansetron, Inhaled Placebo
- Other · Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Buffalo, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 375
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- HIV Infections
- Interventions
- Amprenavir
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 210 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 2
- States / cities
- Fort Lauderdale, Florida • Memphis, Tennessee
- Conditions
- Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
- Interventions
- Finerenone (Kerendia, BAY94-8862)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 22
- States / cities
- Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
- Conditions
- SHANK3 Haploinsufficiency, Phelan-McDermid Syndrome
- Interventions
- JAG201
- Genetic
- Lead sponsor
- Jaguar Gene Therapy, LLC
- Industry
- Eligibility
- 2 Years to 9 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts • New York, New York
- Conditions
- Asthma in Children
- Interventions
- Clinical decision support + education (CDS+) and population health management (PHM), Control
- Behavioral · Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Attention Deficit Disorder With Hyperactivity
- Interventions
- NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg
- Drug
- Lead sponsor
- Aevi Genomic Medicine, LLC, a Cerecor company
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 3
- States / cities
- Maitland, Florida • Miami, Florida • Las Vegas, Nevada
- Conditions
- Airway Management, Infant ALL, Children, Only, Endotracheal Intubation
- Interventions
- Airway positioning per specified protocol followed by Direct Laryngoscopy and Endotracheal Intubation, Airway positioning per provider preference followed by Direct Laryngoscopy and Endotracheal Intubation
- Procedure
- Lead sponsor
- Tufts Medical Center
- Other
- Eligibility
- 1 Month to 48 Months
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Polyethylene Glycols, Children, Only
- Interventions
- PEG 3350
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 16 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Amblyopia
- Interventions
- Binocular video games, Patching of the sound eye
- Device
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 4 Years to 12 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 5
- States / cities
- Gainesville, Florida • Maitland, Florida • Chicago, Illinois + 2 more
- Conditions
- Sleep Apnea, Obstructive, Hypotonia, Child, Only
- Interventions
- ssNPA
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 3 Years to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Cytomegalovirus Prophylaxis
- Interventions
- Letermovir
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 15 more
- Conditions
- Iron Deficiency Anemia
- Interventions
- elemental iron (NovaFerrum®), elemental iron (Ferrous Sulfate)
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 9 Months to 48 Months
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Pediatric Epilepsy
- Interventions
- Depakote Delayed-Release/Depakote Sprinkle, Depakote ER
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Malnutrition, Child, Malnutrition, Essential Fatty Acid Deficiency (EFAD), Parenteral Nutrition Associated Cholestasis
- Interventions
- SMOFlipid® (lipid injectable emulsion)
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 2 more
- Conditions
- Single Sided Deafness, Unilateral Deafness, Hearing Loss, Unilateral, Hearing Loss, Congenital Hearing Loss, Deafness One Ear
- Interventions
- Cochlear Implant
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 7 Months to 71 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Fragile X Syndrome
- Interventions
- AFQ056
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 3 Years to 11 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 3
- States / cities
- Sacramento, California • Chicago, Illinois • Nashville, Tennessee
- Conditions
- Hepatic Impairment
- Interventions
- ABL001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 3
- States / cities
- Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
- Conditions
- Autism Spectrum Disorders
- Interventions
- Intranasal Oxytocin, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 5 Years to 40 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Rabies
- Interventions
- KamRAB - HRIG
- Drug
- Lead sponsor
- Kamada, Ltd.
- Industry
- Eligibility
- 0 Years to 17 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Healthy Female Participants
- Interventions
- Zibotentan, EE/LNG
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Brooklyn, Maryland
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- D46cpΔM2-2 vaccine, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 60 Months
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- ADHD
- Interventions
- Methylphenidate Hydrochloride ER, Behavioral classroom, Placebo, General Classroom, Academic Accommodations
- Drug · Behavioral
- Lead sponsor
- Florida International University
- Other
- Eligibility
- 5 Years to 12 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Amherst, New York
- Conditions
- RSV Infection
- Interventions
- RSV 6120/∆NS1, RSV 6120/F1/G2/∆NS1, Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 6 Months to 59 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland